> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer Alopecia Therapy Granted Breakthrough
- URL: https://www.fdaweb.com/pfizer-alopecia-therapy-granted-breakthrough/
- Published: 2018-09-05T12:00:00.000Z
- Updated: 2026-09-15T00:29:54.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142274

FDA has granted Pfizer a breakthrough therapy designation for its investigational oral Janus kinase 3 inhibitor PF-06651600 for treating patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body. The designation was supported by positive results from a Phase 2 study, which will be presented during a 9/15 European Academy of Dermatology and Venerology Congress in Paris. Currently, there are no FDA-approved treatments for alopecia areata, the company says. PF-06651600 is also under investigation for treating rheumatoid arthritis, Crohn’s disease and ulcerative colitis.